Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma

55 Citations (Scopus)


Personalized cancer immunotherapy based on infusion of T cells holds the promise to specifically target a patient's individual tumor. Accumulating evidence indicates that the T cells mediating these tumor regressions after cancer immunotherapies may primarily target patient-specific mutations expressed by the patients' tumors and that the presence of these "neo-antigen" specific T-cells may be related to a high number of mutations in the tumor. In melanoma, treatment with autologous tumor-infiltrating lymphocytes (TILs) can mediate durable complete responses. Previous trials investigating TIL therapy in solid tumors other than melanoma have shown limited success, however none of these early trials used current preparative chemotherapy regimens, and the methods for in vitro lymphocyte expansion have changed considerably. New advances and understandings in T cell based immunotherapies have stimulated the interest in developing this approach for other indications. Here, we summarize the early clinical data in the field of adoptive cell transfer therapy (ACT) using tumor-infiltrating lymphocytes for patients with renal cell carcinoma (RCC) and ovarian cancer (OC). In addition we describe the major advances in the characterization and application of TIL therapy for patients with RCC and OC.

Original languageEnglish
JournalHuman vaccines & immunotherapeutics
Issue number12
Pages (from-to)2790-5
Number of pages6
Publication statusPublished - 2 Dec 2015


Dive into the research topics of 'Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma'. Together they form a unique fingerprint.

Cite this